Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE
Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc
Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRocView Video
Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors
Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investorsView Video

Latest Share Chat

UPDATE 1-EU pays 336 mln euros to secure AstraZeneca's potential COVID-19 vaccine

Thu, 27th Aug 2020 16:49

(Adds details, combines two stories)

By Francesco Guarascio

BRUSSELS, Aug 27 (Reuters) - The European Commission has
made a 336 million euros ($396 million) downpayment to British
drug maker AstraZeneca to secure at least 300 million
doses of its potential COVID-19 vaccine, a spokesman said on
Thursday.

The deal covers development, liability and other costs faced
by the vaccine maker. The EU has also secured an option to buy
100 million additional doses of the vaccine under development.

The 27 EU states could buy it at a later stage, should the
vaccine prove successful.

The overall price they will pay to acquire the doses has not
been revealed, but under an earlier deal struck in June with
AstraZeneca by Germany, France, Italy and the Netherlands, all
members of the EU, AstraZeneca agreed to sell 300 million doses
for 750 million euros ($843 million).

The EU deal completed the preliminary accord reached with
the drug maker by the four countries, the Commission said in a
statement.

"We cannot indicate at this stage the specific pricing per
dose. However, a significant part of the overall costs are
funded by a contribution from the overall ESI funding for
vaccines," the commission spokesman said, referring to the 336
million euros paid through the bloc's so-called emergency
support instrument.

It is the first contract signed by the EU with a maker of
potential COVID-19 vaccines. Brussels was previously said to be
in advanced talks with Johnson & Johnson, Sanofi
, Moderna and CureVac for their
potential vaccines.

EU officials told Reuters in July the bloc was also talking
with Pfizer and BionTech for the shot they are
developing together.

The contract with AstraZeneca follows an advance purchase
agreement signed by Brussels with the company earlier in August
.

Part of the money the EU pays for supply deals covers legal
risks faced by vaccine makers if their shots have unexpected
side effects. These risks are increased by the hastened process
to develop a vaccine in the race against the COVID-19 pandemic.

"In order to compensate for such high risks taken by
manufacturers, the Advanced Purchase Agreements provide for
member states to indemnify the manufacturer for liabilities
incurred under certain conditions," the commission said.

"Liability still remains with the companies," it added.

This issue has been one of the stumbling blocs in talks with
other vaccine makers, official told Reuters, as companies prefer
to have a broader shield.

($1 = 0.8479 euros)
(Reporting by Francesco Guarascio
Additional reporting by Josephine Mason
Editing by Jan Harvey and David Holmes)

Related Shares

More News
27 Mar 2024 12:02

LONDON MARKET MIDDAY: FTSE 100 underperforms ahead of US PCE data

(Alliance News) - Stock prices in London were lower at midday on Wednesday, but trade was more confident in mainland Europe, with focus turning to the...

27 Mar 2024 11:56

C4X Discovery seeks AIM delisting but half-year revenue skyrockets

(Alliance News) - C4X Discovery Holdings PLC shares plunged on Wednesday after it said it plans to delist from AIM in London, due to "the recent downt...

27 Mar 2024 09:19

AstraZeneca treatments become "first and only" to be approved in Japan

(Alliance News) - AstraZeneca PLC announced on Wednesday the approval of two of its treatments for use in Japan.

27 Mar 2024 09:03

LONDON MARKET OPEN: FTSE 100 slips as unease lingers before US data

(Alliance News) - Stock prices in London edged lower after the open on Wednesday, with some nervy trade ahead of a US inflation reading later in the w...

27 Mar 2024 08:02

LONDON BRIEFING: Diploma makes buy; Astra wins Japan drug approvals

(Alliance News) - Stocks in London opened in a muted fashion on Wednesday, with some unease lingering in equity markets ahead of a US inflation readin...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.